Publications by authors named "Isabel Bover"

Claim this Profile
O
Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: the Greko II study (GETHI2013-01).
Jesus Garcia-Donas, Laia Garrigos, Nuria Lainez, Ana Santaballa, Andres Redondo, Isabel Bover

Clin Transl Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Open-label phase II clinical trial of ketoconazole as CYP17 inhibitor in metastatic or advanced non-resectable granulosa cell ovarian tumors: the GREKO (GRanulosa Et KetOconazole) trial, GETHI 2011-03.
Jesus Garcia-Donas, Alicia Hurtado, Laia Garrigos, Ana Santaballa, Andres Redondo, Isabel Bover

Clin Transl Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: final results of a randomised phase 2 clinical trial.
Cesare Gridelli, Tudor Ciuleanu, Manuel Domine, Aleksandra Szczesna, Isabel Bover

Br J Cancer· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer.
Ignacio Romero, Pedro Mallol, Ana Santaballa, Jose M Del Campo, Marta Mori, Isabel Bover

Anticancer Drugs· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial.
Michel Fabbro, Kathleen N Moore, Anne Dørum, Anna V Tinker, Sven Mahner, Isabel Bover

Gynecol Oncol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of a Streamlined Oncologist-Led BRCA Mutation Testing and Counseling Model for Patients With Ovarian Cancer.
Nicoletta Colombo, Gloria Huang, Giovanni Scambia, Eva Chalas, Sandro Pignata, Isabel Bover

J Clin Oncol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lung Cancer in Women with a Family History of Cancer: The Spanish Female-specific Database WORLD07.
Dolores Isla, Enriqueta Felip, Nuria Viñolas, Mariano Provencio, Margarita Majem, Isabel Bover

Anticancer Res· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE).
Christian Kurzeder, Isabel Bover, Frederik Marmé, Joern Rau, Patricia Pautier

J Clin Oncol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.
Niki Karachaliou, Clara Mayo-de las Casas, Cristina Queralt, Itziar de Aguirre, Boris Melloni, Isabel Bover

JAMA Oncol· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Initial activation status of the antioxidant response determines sensitivity to carboplatin/paclitaxel treatment of ovarian cancer.
Daniel G Pons, Jorge Sastre-Serra, Mercedes Nadal-Serrano, Aina Oliver, Magdalena García-Bonafé, Isabel Bover

Anticancer Res· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.
Suresh S Ramalingam, Fiona Blackhall, Maciej Krzakowski, Carlos H Barrios, Keunchil Park, Isabel Bover

J Clin Oncol· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rafael Rosell, Enric Carcereny, Radj Gervais, Alain Vergnenegre, Bartomeu Massuti, Isabel Bover

Lancet Oncol· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fifth Educational Symposium of the Spanish Lung Cancer Group: report on the Molecular Biology Workshop.
Isabel Bover, Christian Rolfo, Eloisa Jantus-Lewintre, Rafael Sirera, Carlos Camps

Lung Cancer· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SEOM guidelines for the treatment of malignant pleural mesothelioma.
Pilar Lianes, Jordi Remon, Isabel Bover, Dolores Isla

Clin Transl Oncol· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study.
Tudor Ciuleanu, Thomas Brodowicz, Christoph Zielinski, Joo Hang Kim, Maciej Krzakowski, Isabel Bover

Lancet· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Screening for epidermal growth factor receptor mutations in lung cancer.
Rafael Rosell, Teresa Moran, Cristina Queralt, Rut Porta, Felipe Cardenal, Isabel Bover

N Engl J Med· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Induction chemotherapy with cisplatin and gemcitabine followed by concurrent chemoradiation with twice-weekly gemcitabine in unresectable stage III non-small cell lung cancer: final results of a phase II study.
Remei Blanco, Josep Solé, Jesús Montesinos, Carlos Mesía, Manuel Algara, Isabel Bover

Lung Cancer· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas.
Xavier Garcia del Muro, Antonio Lopez-Pousa, Javier Martin, Jose M Buesa, Javier Martinez-Trufero, Isabel Bover

Cancer· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of the methylenetetrahydrofolate reductase C677T polymorphism on patients with cisplatin/gemcitabine-treated stage IV non-small-cell lung cancer.
Vicente Alberola, Carme Sarries, Rafael Rosell, Miquel Taron, Ramon de las Peñas, Isabel Bover

Clin Lung Cancer· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis